These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 9514177)

  • 41. The antithrombotic effects of CI-1028, an orally bioavailable direct thrombin inhibitor, in a canine model of venous and arterial thrombosis.
    McClanahan TB; Hicks GW; Ignasiak DP; Bousley R; Mertz TE; Juneau P; Janiczek-Dolphin N; Kim IC; Gallagher KP
    J Thromb Thrombolysis; 2000 Dec; 10(3):277-84. PubMed ID: 11122549
    [TBL] [Abstract][Full Text] [Related]  

  • 42. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers.
    Johansson LC; Andersson M; Fager G; Gustafsson D; Eriksson UG
    Clin Pharmacokinet; 2003; 42(5):475-84. PubMed ID: 12739985
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
    Roux S; Tschopp T; Baumgartner HR
    J Pharmacol Exp Ther; 1996 Apr; 277(1):71-8. PubMed ID: 8613969
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding.
    Konishi N; Hiroe K; Kawamura M
    Thromb Haemost; 2010 Sep; 104(3):504-13. PubMed ID: 20664909
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.
    Gustafsson D; Elg M
    Thromb Res; 2003 Jul; 109 Suppl 1():S9-15. PubMed ID: 12818629
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
    Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin.
    Furugohri T; Morishima Y
    Thromb Res; 2015 Sep; 136(3):658-62. PubMed ID: 26188924
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA; Lee P; Rios G; Kottke-Marchant K; Topol EJ
    Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.
    Wienen W; Stassen JM; Priepke H; Ries UJ; Hauel N
    J Thromb Haemost; 2007 Jun; 5(6):1237-42. PubMed ID: 17362226
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
    Schneider J; Hauser R; Hennies HH; Korioth J; Steffens G; Wnendt S
    Thromb Haemost; 1997 Mar; 77(3):535-9. PubMed ID: 9066007
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig.
    Eriksson M; Larsson A; Saldeen T; Mattsson C
    Thromb Haemost; 1998 Dec; 80(6):1022-6. PubMed ID: 9869178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
    Christersson C; Oldgren J; Bylock A; Wallentin L; Siegbahn A
    J Thromb Haemost; 2005 Oct; 3(10):2245-53. PubMed ID: 16194202
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.
    Eur Heart J; 1997 Sep; 18(9):1416-25. PubMed ID: 9458447
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
    Nichols WW; Nicolini FA; Khan S; Saldeen TG; Mehta JL
    Am Heart J; 1993 Aug; 126(2):285-92. PubMed ID: 7687816
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.
    Johansson S; Wåhlander K; Larson G; Ohlsson L; Larsson M; Eriksson UG
    Blood Coagul Fibrinolysis; 2003 Oct; 14(7):677-84. PubMed ID: 14517494
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin.
    Duval N; Lunven C; O'Brien DP; Grosset A; O'Connor SE; Berry CN
    Br J Pharmacol; 1996 Jun; 118(3):727-33. PubMed ID: 8762100
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis.
    Sarich TC; Osende JI; Eriksson UG; Fager GB; Eriksson-Lepkowska M; Ohlsson L; Carlsson S; Wåhlander K; Gustafsson D; Badimon JJ
    J Thromb Haemost; 2003 May; 1(5):999-1004. PubMed ID: 12871368
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antithrombotic effects of BCH 2763, a new direct thrombin inhibitor, in a canine model of venous thrombosis.
    McClanahan TB; Ignasiak DP; Juneau P; Finkle C; Winocour PD; Gallagher KP
    J Thromb Thrombolysis; 1999 Jun; 7(3):301-6. PubMed ID: 10375391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
    Guth BD; Müller TH
    Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.
    Gustafsson D; Nyström J; Carlsson S; Bredberg U; Eriksson U; Gyzander E; Elg M; Antonsson T; Hoffmann K; Ungell A; Sörensen H; Någård S; Abrahamsson A; Bylund R
    Thromb Res; 2001 Feb; 101(3):171-81. PubMed ID: 11228340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.